Compare MIRM & EPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | EPR |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.4B |
| IPO Year | 2019 | 1997 |
| Metric | MIRM | EPR |
|---|---|---|
| Price | $64.32 | $50.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $87.55 | $57.06 |
| AVG Volume (30 Days) | 616.7K | ★ 620.3K |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 7.12% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.29 |
| Revenue | $471,794,000.00 | ★ $707,150,000.00 |
| Revenue This Year | $53.78 | $5.11 |
| Revenue Next Year | $19.91 | $2.70 |
| P/E Ratio | ★ N/A | $21.77 |
| Revenue Growth | ★ 53.66 | 3.73 |
| 52 Week Low | $36.88 | $41.75 |
| 52 Week High | $78.55 | $61.24 |
| Indicator | MIRM | EPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.49 | 38.11 |
| Support Level | $63.66 | $49.41 |
| Resistance Level | $66.77 | $51.80 |
| Average True Range (ATR) | 2.99 | 0.93 |
| MACD | -0.69 | -0.15 |
| Stochastic Oscillator | 9.63 | 20.14 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.